212141-51-0 | Vatalanib dihydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$10.00	$7.00
10mg	98%	in stock	$36.00	$25.00
50mg	98%	in stock	$99.00	$69.00
100mg	98%	in stock	$148.00	$103.00
250mg	98%	in stock	$246.00	$172.00
1g	98%	in stock	$556.00	$390.00
5g	98%	in stock	$1,878.00	$1,315.00

Description

• Catalog Number: AF32642
• Chemical Name: Vatalanib dihydrochloride
• CAS Number: 212141-51-0
• Molecular Formula: C20H17Cl3N4
• Molecular Weight: 419.7348
• MDL Number: MFCD08458964
• SMILES: Clc1ccc(cc1)Nc1nnc(c2c1cccc2)Cc1ccncc1.Cl.Cl

Computed Properties

• Complexity: 407
• Covalently-Bonded Unit Count: 3
• Heavy Atom Count: 27
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 4

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

  British journal of cancer 20120925

• [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].

  Magyar onkologia 20120901

• Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

  Lung cancer (Amsterdam, Netherlands) 20120601

• Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats.

  Neurochemistry international 20120501

• Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].

  Magyar onkologia 20120301

• Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

  Current cancer drug targets 20111101

• A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.

  Clinical advances in hematology & oncology : H&O 20111101

• HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.

  PLoS genetics 20111001

• Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.

  Leukemia research 20110901

• Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.

  World journal of gastroenterology 20110821

• Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110715

• Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.

  Journal of neuro-oncology 20110601

• Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

  British journal of cancer 20110524

• Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• Vatalanib in advanced colorectal cancer: two studies with identical results.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110520

• A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.

  Cancer investigation 20110501

• The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRβ pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis.

  The American journal of pathology 20110401

• Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.

  Annals of surgical oncology 20110201

• Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.

  Cancer chemotherapy and pharmacology 20110101

• In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.

  PloS one 20110101

• Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.

  Radiation oncology (London, England) 20110101

• Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.

  Cancer 20101101

• Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20101101

• A phase 2 study of vatalanib in metastatic melanoma patients.

  European journal of cancer (Oxford, England : 1990) 20101001

• PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

  Genes & development 20101001

• Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100815

• A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20100801

• Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant.

  Leukemia & lymphoma 20100801

• Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia.

  Journal of vascular surgery 20100801

• VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane.

  Microcirculation (New York, N.Y. : 1994) 20100801

• The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100701

• Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

  Cancer biology & therapy 20100601

• [Effects of PTK787 on cell proliferation and expression of fak mRNA in K562].

  Zhongguo shi yan xue ye xue za zhi 20100601

• A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.

  Anticancer research 20100601

• Molecular therapy of pancreatic cancer.

  Minerva endocrinologica 20100301

• Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.

  Neoplasia (New York, N.Y.) 20100201

• EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.

  European journal of cancer (Oxford, England : 1990) 20100101

• Chemical constituents from Clematis delavayi var. spinescens.

  Molecules (Basel, Switzerland) 20091105

• A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101

• Drug release from MCC- and carrageenan-based pellets: experiment and theory.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20091001

• Evaluation of the drug release patterns and long term stability of aqueous and organic coated pellets by using blends of enteric and gastrointestinal insoluble polymers.

  International journal of pharmaceutics 20091001

• Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258.

  Laboratory investigation; a journal of technical methods and pathology 20091001

• Anti-angiogenic therapies for metastatic colorectal cancer.

  The Cochrane database of systematic reviews 20090708

• PTK787/ZK 222584 inhibits tumor growth promoting mesenchymal stem cells: kinase activity profiling as powerful tool in functional studies.

  Cancer biology & therapy 20090701

• The selective VEGFR inhibitor PTK787/ZK 222584 represses the activities of VEGFR-negative bone marrow-derived mesenchymal stem cells.

  Cancer biology & therapy 20090701

• The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.

  Cancer research 20090601

• Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.

  Experimental hematology 20090601

• Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

  Cancer 20090515

• Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.

  The oncologist 20090501

• Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis.

  American journal of physiology. Heart and circulatory physiology 20090301

• mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090301

• Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory.

  Brain research 20090223

• 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.

  Bioorganic & medicinal chemistry letters 20090215

• A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.

  Investigational new drugs 20090201

• PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.

  Laboratory investigation; a journal of technical methods and pathology 20090201

• Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.

  Molecular cancer therapeutics 20090101

• Effect of PTK/ZK on the angiogenic switch in head and neck tumors.

  Journal of dental research 20081201

• Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.

  The American journal of pathology 20081001

• Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080901

• Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines.

  Molecules (Basel, Switzerland) 20080624

• Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity.

  Bioorganic & medicinal chemistry letters 20080501

• Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.

  Investigative ophthalmology & visual science 20080501

• Vascular endothelial growth factor in chronic rat allograft nephropathy.

  Transplant immunology 20080501

• [Antibody treatment in colorectal cancer--what the surgeon needs to know].

  Zentralblatt fur Chirurgie 20080401

• A conserved role of the VEGF pathway in angiogenesis of an ectodermally-derived vasculature.

  Developmental biology 20080301

• Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080101

• Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.

  Anti-cancer drugs 20080101

• [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

  Bulletin du cancer 20080101

• Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.

  International journal of cancer 20071215

• New approaches in angiogenic targeting for colorectal cancer.

  World journal of gastroenterology 20071128

• Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.

  Biochimica et biophysica acta 20070901

• Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.

  Bioorganic & medicinal chemistry letters 20070701

• PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.

  Leukemia research 20070701

• Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.

  The Journal of dermatology 20070701

• [Oral drugs inhibiting the VEGF pathway].

  Bulletin du cancer 20070701

• [Anti-angiogenic treatment and colorectal cancer].

  Bulletin du cancer 20070701

• Novel agents and targets for the therapy of advanced colon cancer.

  Clinical advances in hematology & oncology : H&O 20070501

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.

  Reviews on recent clinical trials 20070501

• A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070401

• Biological therapy update in colorectal cancer.

  Expert opinion on biological therapy 20070401

• Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.

  The oncologist 20070401

• Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours.

  Expert opinion on investigational drugs 20070301

• Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis.

  Clinical colorectal cancer 20070301

• Rationale and clinical results of multi-target treatments in oncology.

  The International journal of biological markers 20070101

• 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.

  Chemical biology & drug design 20061201

• Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules.

  Journal of controlled release : official journal of the Controlled Release Society 20061128

• Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.

  American journal of respiratory and critical care medicine 20061115

• Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.

  Drug metabolism and disposition: the biological fate of chemicals 20061101

• Rational design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium.

  ChemMedChem 20061101

• Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.

  AJR. American journal of roentgenology 20061001

• High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.

  Molecular cancer therapeutics 20060901

• Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.

  Nature medicine 20060801

• Biological agents versus chemotherapy in the treatment of colorectal cancer.

  Expert opinion on pharmacotherapy 20060701

• Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

  Cancer chemotherapy and pharmacology 20060601

• Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

  Leukemia 20060601

• Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

• A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.

  British journal of cancer 20060522

• Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.

  Head & neck 20060501

• [Molecular targets in colon cancer].

  Therapeutische Umschau. Revue therapeutique 20060401

• Vascular endothelial growth factor receptor signaling is required for cardiac valve formation in zebrafish.

  Developmental dynamics : an official publication of the American Association of Anatomists 20060101

• Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

  Cancer research 20060101

• Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.

  Reviews on recent clinical trials 20060101

• Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.

  IDrugs : the investigational drugs journal 20051201

• Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.

  IDrugs : the investigational drugs journal 20051201

• Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.

  Cancer research 20051201

• Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.

  The Laryngoscope 20051201

• Update on angiogenesis inhibitors.

  Current opinion in oncology 20051101

• Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.

  IDrugs : the investigational drugs journal 20051001

• Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.

  Clinical lung cancer 20050901

• PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

  NMR in biomedicine 20050801

• Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.

  Cancer research 20050615

• The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050615

• Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice.

  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20050601

• Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

  European journal of cancer (Oxford, England : 1990) 20050601

• Angiogenesis and lung cancer: prognostic and therapeutic implications.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050510

• Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

  Cancer research 20050501

• Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.

  Clinical colorectal cancer 20050501

• Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050401

• Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice.

  International journal of radiation oncology, biology, physics 20050301

• PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.

  Chembiochem : a European journal of chemical biology 20050301

• Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).

  Academic radiology 20050301

• Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.

  IDrugs : the investigational drugs journal 20050301

• Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.

  Seminars in oncology 20050201

• Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation.

  Transplantation 20050127

• [Problems in the current target therapy of malignancies].

  Voprosy onkologii 20050101

• The fight against cancer: the next round.

  Drug discovery today 20041115

• Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.

  Nature medicine 20041101

• A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20041001

• Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.

  Clinical colorectal cancer 20041001

• Future directions with angiogenesis inhibitors in colorectal cancer.

  Clinical colorectal cancer 20041001

• The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

  Cancer research 20040915

• Protein kinase inhibitors: novel tools in cancer therapy.

  Der Urologe. Ausg. A 20040901

• Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.

  Clinical lung cancer 20040901

• Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.

  Lung cancer (Amsterdam, Netherlands) 20040801

• PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.

  Neurosurgery 20040801

• Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.

  Oncogene 20040603

• An image worth a thousand lives?

  Nature biotechnology 20040601

• Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20040401

• Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.

  Endocrinology 20040301

• Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?

  International journal of radiation oncology, biology, physics 20040201

• Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.

  Clinical & experimental metastasis 20040101

• Antiangiogenic therapy: more promise and, yet again, more questions.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031101

• Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031101

• [Current screening for molecular target therapy of cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20031101

• Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer.

  Clinical colorectal cancer 20031101

• Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.

  Bioorganic & medicinal chemistry letters 20030915

• The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies.

  Investigative ophthalmology & visual science 20030801

• PTK/ZK (Novartis).

  IDrugs : the investigational drugs journal 20030801

• American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.

  IDrugs : the investigational drugs journal 20030701

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.

  Seminars in oncology 20030601

• MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.

  European journal of nuclear medicine and molecular imaging 20030301

• p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3.

  Genes & development 20030215

• Novel therapies for multiple myeloma.

  British journal of haematology 20030101

• Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor.

  Arteriosclerosis, thrombosis, and vascular biology 20030101

• American Society of Hematology--44th Annual Meeting and Exposition. Drug highlights I. 6-10 December 2002, Philadelphia, PA, USA.

  IDrugs : the investigational drugs journal 20030101

• Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation.

  Anticancer research 20030101

• Inhibitors of the vascular endothelial growth factor receptor.

  Hematology/oncology clinics of North America 20021001

• New drugs in acute myeloid leukemia.

  Current oncology reports 20020901

• The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

  Cancer research 20020901

• MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model.

  Academic radiology 20020801

• PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

  Cancer research 20020715

• Quantitative and qualitative in vivo angiogenesis assay.

  International journal of oncology 20020701

• Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis.

  Circulation 20020528

• Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.

  Cancer research 20020401

• Dissection of angiogenic signaling in zebrafish using a chemical genetic approach.

  Cancer cell 20020401

• Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.

  The Journal of pharmacology and experimental therapeutics 20011201

• Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.

  British journal of cancer 20011201

• Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.

  Cancer biotherapy & radiopharmaceuticals 20011001

• New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

  Journal of medicinal chemistry 20000615

• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  Cancer research 20000415